micro-community-banner
 
  • Saved

3yr

A new ex vivo skin model for mechanistic understanding of putative anti-inflammatory topical therapeutics

Source : https://doi.org/10.1016/j.ijpharm.2022.121610


Highlights:
•Human ex vivo skin culture can be stimulated with cytokine cocktails to induce specific T cell mediated inflammatory states.
•The induced inflammatory state in HESC incorporates multiple immune cell pathways as well as chemokine and cell barrier function gene signaling.
•Gene expression profiles elicited in the HESC...

  • Saved

3yr

Blood transcriptome profiling identifies two candidate endotypes of atopic dermatitis

Source : https://doi.org/10.1016/j.jaci.2022.02.001


Conclusion: Our observations indicate that AD can be stratified into eosinophilic and non-eosinophilic endotypes and might be an incentive for stratified trial designs and treatment strategies.


  • 3yr
    Would be interested in seeing where this go and looking ahead and subtypes of eosinophilic and non-eosinophilic endotypes and treatment implications
  • 3yr
    Key Points • Source: The Journal of Allergy and Clinical Immunology • Conclusion/Relevance: “Our observations indicate that AD [atopic dermatitis] can be stratified into eosinophilic and non-eosinophilic endotypes and might be an incentive for Show More
  • Saved

3yr
NF-κB perturbation reveals unique immunomodulatory functions in Prx1+ fibroblasts that promote development of atopic dermatitis

NF-κB perturbation reveals unique immunomodulatory functions in Prx1+ fibroblasts that promote development of atopic dermatitis

Source : https://www.science.org/doi/10.1126/scitranslmed.abj0324

The early events of atopic dermatitis (AD) are not fully elucidated, but immunomodulatory fibroblast subsets may contribute to disease. Here, Ko and colleagues deleted Ikkb in fibroblastic cells in mice...


Monoclonal antibody treatment against CCL11 was effective in reducing the eosinophilia and TH2 inflammation in a mouse model. Together, the murine model and human AD specimens point to dysregulated Prx1 fibroblasts as a previously unrecognized etiologic factor that may contribute to the pathogenesis of AD and suggest that targeting CCL11 may be...

  • 3yr
    Interesting research on the target of CCL11 to treat AD and like dx
  • Saved

3yr
Long-term outcome of corneal collagen crosslinking with riboflavin and UV-A irradiation for keratoconus

Long-term outcome of corneal collagen crosslinking with riboflavin and UV-A irradiation for keratoconus

Source : https://www.medrxiv.org/content/10.1101/2022.02.05.22270507v1

Purpose To evaluate long-term outcomes of corneal collagen crosslinking (CXL) using riboflavin and UV-A irradiation and to determine when to repeat CXL. Methods In this retrospective consecutive interventional case series...


Conclusions: CXL can slow or stop keratoconus progression. However, as the number of responders declines after 5 years, patients with risk factors may require re-treatment.


  • Saved

3yr

Ruxolitinib cream in the treatment of cutaneous lichen planus: A prospective, open-label study

Source : https://doi.org/10.1016/j.jid.2022.01.015


In this small pilot study, topical ruxolitinib was highly effective in the treatment of cutaneous LP. Transcriptomic analysis confirmed LP as an interferon-driven disease and downregulation of ISGs correlated with disease response.